A retrospective cohort study led by Omer S. Ashruf, BS, and colleagues from the Cleveland Clinic and Northeast Ohio Medical University found that glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are associated with a significantly lower risk of hematologic malignancies, particularly myelodysplastic syndromes and myeloproliferative neoplasms, in patients with type 2 diabetes (T2D). The study suggests that GLP-1 RAs may offer a promising novel strategy for reducing cancer risk, but further prospective studies are needed to explore their biological mechanisms.

Source: JAMA Network Open